UK markets open in 6 hours 38 minutes
NIKKEI 225
38,887.49 +397.32 (+1.03%) HANG SENG
18,424.96 -19.15 (-0.10%) CRUDE OIL
74.56 +0.49 (+0.66%) GOLD FUTURES
2,373.80 -1.70 (-0.07%) DOW
38,807.33 +96.04 (+0.25%) Bitcoin GBP
55,581.62 +482.20 (+0.88%)
MorphoSys AG (MOR.DE)
XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
At close: 05:35PM CEST
| Previous close | 67.70 |
| Open | 67.75 |
| Bid | 67.75 x 1500 |
| Ask | 67.80 x 8800 |
| Day's range | 67.65 - 68.20 |
| 52-week range | 14.52 - 69.75 |
| Volume | |
| Avg. volume | 237,248 |
| Market cap | 2.569B |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.53 |
| Earnings date | 07 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 56.00 |
ZacksBiogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
Simply Wall St.MorphoSys (ETR:MOR) shareholders have earned a 228% return over the last year
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
Business WireMorphoSys AG Reports First Quarter 2024 Financial Results
PLANEGG/MUNICH, Germany, April 29, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
© 2024 Yahoo. All rights reserved.